TD Asset Management Inc Acquires 208 Shares of Zoetis Inc. $ZTS

TD Asset Management Inc raised its holdings in Zoetis Inc. (NYSE:ZTS) by 0.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,583,957 shares of the company’s stock after buying an additional 208 shares during the quarter. TD Asset Management Inc owned 0.36% of Zoetis worth $247,018,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Nova Wealth Management Inc. bought a new stake in Zoetis in the 1st quarter valued at $25,000. 1248 Management LLC bought a new stake in shares of Zoetis in the 1st quarter worth about $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the 1st quarter worth about $29,000. Cornerstone Planning Group LLC increased its position in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC increased its position in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $142.29 on Tuesday. The company has a market capitalization of $63.06 billion, a price-to-earnings ratio of 24.49, a P/E/G ratio of 2.26 and a beta of 0.90. The firm’s 50 day simple moving average is $149.04 and its 200 day simple moving average is $154.19. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 34.42%.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZTS. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and dropped their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Argus reiterated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus target price of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.